Retrospective study finds that poor interim FDG-PET/CT tumor response predicts shorter progression-free survival in limited-stage small-cell lung cancer, suggesting a tool for adaptive therapy.
Purpose Evaluation of interim-[ 18 F]FDG-PET/CT as a prognostic tool in limited disease small cell lung cancer (SCLC). Methods We included 35 patients with limited disease SCLC from a prospective institutional registry in this retrospective study. Patients received induction chemotherapy (3–4 cycles) followed by concurrent radiochemotherapy. Baseline [ 18 F]FDG-PET/CT was performed before or shortly after start of induction chemotherapy, interim PET/CT was acquired during late induction or concurrent chemoradiotherapy. Maximum standardized uptake value (SUV max ), metabolic target volume (MTV), and total lesion glycolysis values (TLG) were determined. An exponential decay model with an asymptotic offset was used to describe treatment response over time. Deviations > 2 standard deviations (SD) above model-predicted means after day 30 were considered poor response. Progression-free survival (PFS) was analyzed. Results All patients underwent twice-daily radiotherapy to a base dose of 45 Gy. SUV max showed greater inter-patient variability than MTV. Poor treatment response was observed in 17%, 31%, or 14% at the SUV max , MTV and TLG endpoints. Deviations > 2 SD from the model in SUV max and TLG were significantly associated with shorter PFS ( p = 0.0003, p = 0.0014); MTV was not prognostic ( p = 0.2630). Leave-one-out cross-validation (LOOCV) could confirm the prognostic value of the standardized residual SUV max larger than 2 standard deviations above model estimate as negative PFS predictor ( p = 0.0152, Fishers exact test). Conclusion Our decay model enables the characterization of [ 18 F]FDG-PET/CT response parameters from scans acquired at variable time points during induction chemotherapy and at start of concurrent radiochemotherapy. Poor SUV max or TLG response was predictive of PFS. Interim-[ 18 F]FDG-PET/CT response may guide individualized treatment adaptation.
No takes yet. Share an insight, caveat, or question.
Hoffmann et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: